Trials / Not Yet Recruiting
Not Yet RecruitingNCT07481604
Safety and Immunogenicity of CVI-VZV-001 in Adults Aged 50 Years and Above
A Multicenter, Active-controlled, Randomized, Double Blinded, Parallel, Phase II Study to Assess the Immunogenicity and Safety of CVI-VZV-001 in Healthy Adults Aged 50 Years and Above
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 135 (estimated)
- Sponsor
- CHA Vaccine Institute Co., Ltd. · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the immunogenicity of the investigational product (IP) in healthy adults aged 50 years or older and to explore differences in immune responses between the experimental and control groups, and to determine the optimal dose of the IP.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Shingrix | Licensed herpes zoster vaccine used as an active comparator. |
| BIOLOGICAL | CVI-VZV-001 | Investigational herpes zoster vaccine. |
Timeline
- Start date
- 2026-04-01
- Primary completion
- 2027-01-01
- Completion
- 2027-01-01
- First posted
- 2026-03-19
- Last updated
- 2026-03-19
Locations
7 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT07481604. Inclusion in this directory is not an endorsement.